|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1.9000 - 1.9900|
|52 Week Range||0.4600 - 6.9600|
|Beta (3Y Monthly)||-5.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Medical Marijuana, Inc. (OTCMKTS:MJNA) has announced that subsidiary Kannaway® has placed a substantial purchase order from AXIM Biotechnologies (OTCMKTS:AXIM) for its CBD nutraceutical chewing gum. Kannaway® creating a nutraceutical brand Kannaway is a lifestyle network offering CBD hemp products. Blake Schroeder, the Chief Executive Officer, said that the subsidiary was proud to work together with […]The post Medical Marijuana, Inc. Affiliate Kannaway In CBD Gum Partnership With AXIM appeared first on Market Exclusive.
SAN DIEGO , Feb. 14, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States , announced that its subsidiary Kannaway® , the first ...
AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (AXIM), a world leader in cannabinoid research and development, today announced that the company has received a significant initial purchase order (“PO”) from Kannaway®, the first hemp lifestyle network to offer cannabidiol (“CBD”) hemp botanical products, for its nutraceutical chewing gum product.
The World Health Organization recommended the re-scheduling of cannabis and some of its main components, recognizing the plant’s medical potential and acknowledging the need for further research around it, only days after the Israel approved a plan to export cannabis. On the markets front, Slang Worldwide Inc (CNSX: SLNG) started trading in Canada. “The successful SLANG Worldwide IPO is just what the cannabis community needed,” Debra Borchardt, CEO of Green Market Report, told Benzinga.
NEW YORK, Jan. 29, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that.
AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (AXIM), a world leader in cannabinoid research and development, today announced the launch of a new corporate website and release of its most recent management presentation, which outlines the Company’s strategic initiatives including the prioritization of its clinical development program by probability of success and fiscal considerations. “One of my first enterprises as CEO of the company was to implement a strategic business plan for the short and midterm that focused our clinical development research on programs with the best chance of success with lesser fiscal obligations,” said AXIM® Biotech CEO, John W. Huemoeller II. “We felt that a redesign of our website and management presentation was an important step in making AXIM’s direction clear and making that information available to our valued shareholders.
NEW YORK, Jan. 08, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the.
OTC:AXIM Summary • AXIM Biotechnologies (OTC:AXIM) holds the intellectual property rights to the controlled-release, trans-mucosal (chewing gum) drug delivery platform for medical cannabinoids. o The company ...